Mitigating inequity: ethically prioritizing patients for CAR T-cell therapy.

Area of Science:

• Oncology
• Hematology
• Health Policy

Background:

• Manufacturing capacity and infrastructure for chimeric antigen receptor T-cell (CAR-T) therapies struggle to meet demand.
• An increasing number of approved CAR-T products and eligible patients create challenges for resource allocation.
• Fair and equitable decision-making frameworks are essential for prioritizing patients for limited CAR-T treatment slots.

Purpose of the Study:

• To apply the Accountability for Reasonableness (A4R) framework to establish fair patient prioritization for CAR-T therapy.
• To develop and implement an ethical framework for managing limited CAR-T treatment capacity.
• To promote transparency and collaboration in resource allocation for CAR-T therapy.

Main Methods:

• Formation of a multidisciplinary working group focused on hematological malignancies.
• Application of A4R guiding principles through multiple rounds of partner engagement.
• Identification of four key prioritization criteria: medical benefit, safety/risk, psychosocial factors, and medical urgency.

Main Results:

• Developed a set of criteria and associated tools for patient prioritization for CAR-T therapy.
• Established an implementation process for the A4R-based prioritization framework.
• Highlighted the importance of fairness and equity in resource allocation, avoiding disadvantage to underserved populations.

Conclusions:

• The A4R framework offers a structured approach to ethically manage limited CAR-T therapy resources.
• Prioritization criteria should encompass medical benefit, safety, psychosocial aspects, and urgency.
• Transparency and adaptability of the framework are crucial for equitable global access to CAR-T therapy.